Clinical trial
A Parallel-group, Phase 2, Randomized, Double-blind, Placebo-controlled, 4-arm, 12-week Trial to Investigate the Efficacy, Safety, and Tolerability of COL-5671-PRO Oral Capsules in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07914231 is registered in ClinicalTrials.gov with Coultreon Biopharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel-group, Phase 2, Randomized, Double-blind, Placebo-controlled, 4-arm, 12-week Trial to Investigate the Efficacy, Safety, and Tolerability of COL-5671-PRO Oral Capsules in Adult Participants With Moderate-to-Severe Plaque Psoriasis
- Lead sponsor
- Coultreon Biopharma
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2027
- Enrollment
- 100 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
plaque psoriasis
Arms
As registered; 4 arms.
-
COL-5671-PRO Treatment A
Participant will receive dose A of COL-5671-PRO capsules orally once daily (QD) for 12 weeks.
-
COL-5671-PRO Treatment B
Participant will receive dose B of COL-5671-PRO capsules orally once daily (QD) for 12 weeks.
-
COL-5671-PRO Treatment C
Participant will receive dose C of COL-5671-PRO capsules orally once daily (QD) for 12 weeks.
-
Placebo
Participant will receive placebo to match COL-5671-PRO capsules orally once daily (QD) for 12 weeks.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Reduction of 75% in PASI score relative to baseline (PASI75) at Week 12
The Psoriasis Area and Severity Index (PASI) combines assessments of the extent of body-surface involvement in 4 anatomical regions (head and neck, upper limbs, trunk, lower limbs) and the severity of erythema, induration, and desquamation in each region, yielding an overall score of 0 to 72. A frequency table of participants with a reduction of 75% in PASI score relative to baseline (PASI75) at Week 12 per intervention arm.
Similar trials
Same condition (Psoriasis) and phase, most recent start first.
+253 more trials See the condition page